Recce Pharmaceuticals Announces Update on Phase I/II Clinical Trial for the Treatment of Burn Wound Infections
December 07, 2021 08:00 ET
|
Recce Pharmaceuticals
Highlights: Broad spectrum antibiotic activity on bacterial burn wound infections with visible infection reduction <24 hours on all patients to dateAll infections cleared within 5 days (acute)...
Recce Pharmaceuticals to Give Opening R&D Address at World Anti-Microbial Resistance Congress 2021
November 08, 2021 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (Company), the Company developing new classes of synthetic anti-infectives, today announced it will...
Recce Pharmaceuticals Receives Ethics Approval to Start Phase I Intravenous Clinical Trial of RECCE® 327
October 26, 2021 08:00 ET
|
Recce Pharmaceuticals
Highlights: Phase I clinical trial of RECCE® 327 approved to start intravenous ascending-dose, randomized, placebo-controlled, parallel, double-blind, single-dose studyAccording to Pew Charitable...
Recce Pharmaceuticals Announces RECCE® 327 Registered in the Australian New Zealand Clinical Trials Registry for Phase I Intravenous Clinical Trial
October 04, 2021 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE) (FSE:R9Q) (Company), the Company developing new classes of synthetic anti-infectives, is pleased to announce...
Recce Pharmaceuticals Announces Anti-Viral Patent Granted in USA for RECCE® Anti-Infectives
July 22, 2021 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, July 22, 2021 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing new classes of synthetic anti-infectives, is pleased to announce the United...
Recce Pharmaceuticals Announces Anti-Viral Patent Granted in China for RECCE® Anti-Infectives
July 21, 2021 08:10 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, July 21, 2021 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing new classes of synthetic anti-infectives, is pleased to announce the Chinese...
Recce Pharmaceuticals Announces Lead Synthetic Anti-infective RECCE® 327 Demonstrates Outstanding Efficacy Against Necrotizing Fasciitis ‘Flesh-Eating’ Bacteria
July 20, 2021 08:00 ET
|
Recce Pharmaceuticals
Highlights RECCE® 327 (R327) shown to reduce deadly ‘flesh-eating’ bacterial count Below Limit of Quantification (BLOQ) within 24 hours, at varying concentrationsR327 BLOQ efficacy as early as 30...
Recce Pharmaceuticals Announces Multiple Patients Dosed with RECCE® 327 in Topical Phase I/II Clinical Trial for the Treatment of Infected Burn Wounds
July 12, 2021 08:00 ET
|
Recce Pharmaceuticals
Highlights: Multiple patients dosed in Phase I/II clinical trial, an important human clinical milestoneNo adverse symptoms reported - R327 well stocked in hospital pharmacy for further patient...
Recce Pharmaceuticals to Present at World Microbe Forum
June 21, 2021 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, June 21, 2021 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE) (FSE:R9Q) (Company), the Company developing new classes of synthetic anti-infectives, has accepted an...
Recce Pharmaceuticals Announces Lead Synthetic Anti-infective RECCE® 327 Demonstrates World First Multiple Mechanisms of Action against E. coli bacteria
June 01, 2021 08:00 ET
|
Recce Pharmaceuticals
Highlights: RECCE® 327 (R327) Mechanism of Action ‘unlike that of any antibiotic seen before’ with multiple mechanisms identified in independent study - to be presented at upcoming World Microbe...